Viruses, the vehicle for cancer gene therapy: A Review

African Journal of Biological Sciences

Nik Mohd Afizan Nik Abd Rahman¹  Nurliyana Mohd Yusof²  Natasha Nur Afiqah Mohamed Noor Fuadi²  Mohd Azuraidi Osman²  Mohd Azmi Mohd Lila³ 

[1] Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia.;Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia;Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia.;

关键词: gene therapy;    viral vector;    adenovirus;    retrovirus;    gene transfer;   

DOI  :  10.33472/AFJBS.2.3.2020.10-19

来源: DOAJ

【 摘 要 】

Cancer diseases are among the world’s leading causes of death, and this global burden is expected to rise in the next two decades. Researchers have been focusing on gene treatment strategy to curb this growing number. To guarantee the success of the gene therapy strategy, therefore, it is essential to develop a suitable delivery agent, notably a viral vector. Despite its benefits, there is also a disadvantage in viral vectors where viruses are hard to cope with their toxicity. Nevertheless, for their long-term expression and stability, viral delivery agents are preferred. To date, among the frequently used vehicles for gene transfer are adenovirus (Ad), adeno-associated virus (AAV), retrovirus, andlentivirus. Each one of these viruses has its own “pros and cons,” rendering them a choice for gene therapy testing. A broad range of gene transfer technologies have been designed over these years, but all transferring technologies still have constraints in clinical applications, and there are no distribution systems that could be implemented in vitro and in vivo in all cell types without any limitations or side effects.

【 授权许可】

Unknown